Toll-like receptors (TLRs) sense microbial products and initiate adaptive immune responses by activating dendritic cells (DCs). As pathogens may contain several TLR agonists, we sought to determine whether different TLRs cooperate in DC activation. In human and mouse DCs, TLR3 and TLR4 potently acted in synergy with TLR7, TLR8 and TLR9 in the induction of a selected set of genes. Synergic TLR stimulation increased production of interleukins 12 and 23 and increased the Delta-4/Jagged-1 ratio, leading to DCs with enhanced and sustained T helper type 1-polarizing capacity. Global gene transcriptional analysis showed that TLR synergy 'boosted' only approximately 1% of the transcripts induced by single TLR agonists. These results identify a 'combinatorial code' by which DCs discriminate pathogens and suggest new strategies for promoting T helper type 1 responses.
Toll-like receptors (TLRs) are innate receptors that sense microbial products and trigger dendritic cell (DC) maturation and cytokine production, thus effectively bridging innate and adaptive immunity 1 . Several characteristics of TLR biology contribute to the efficient microbial detection of immune cells. First, each TLR is triggered by a distinct set of microbial compounds 2 . For example, TLR4 is triggered by lipopolysaccharide (LPS) 3, 4 ; TLR9, by unmethylated oligonucleotide (CpG) 5 ; and TLR3, by double-stranded RNA ('mimicked' by poly(I:C)) 6 . Second, TLRs are differently coupled to signal transduction pathways 7 . With the exception of TLR3, all TLRs are coupled to the MyD88 adaptor; TLR3 and TLR4 also couple to the adaptor TRIF 8 (also called TICAM-1; ref. 9) , which triggers transcription of interferon-b (IFN-b). Other adaptors are differentially recruited by TLR2, TLR3 and TLR4, but their relative functions are less clear [10] [11] [12] [13] [14] . Third, TLRs are localized in different compartments. Although most TLRs are present on the cell surface, TLR7, TLR8 and TLR9 are in the endosomal compartment 15, 16 and TLR3 is intracellular, although its exact location has not yet been defined. Finally, TLRs are expressed in a constitutive or induced way in different cell types, which determines their capacity to detect microbial products [17] [18] [19] .
DCs express the broadest repertoire of TLRs through which they can recognize a plethora of microbial compounds. After challenge with microbial or inflammatory stimuli, immature DCs undergo a complex process of maturation, resulting in their migration from tissues to secondary lymphoid organs and upregulation of major histocompatibility complex (MHC) and costimulatory molecules that are essential for T cell priming 20 . In addition, DCs represent a critical source of interleukin 12 (IL-12), a cytokine that is key in innate responses and drives T helper type 1 (T H 1) polarization 21 . IL-12 production by DCs is tightly controlled, as it requires first a priming signal provided by microbial products or IFN-g and then an amplifying signal provided by T cells through CD40 ligand (CD40L) [22] [23] [24] . Thus, DCs are capable of integrating signals from pathogens, cytokines and T cells, leading to the generation of an adaptive immune response of the appropriate class 25 .
In addition to IL-12, other cues driving T cell differentiation have been described. One such factor is IL-23, which shares the p40 chain with IL-12 but pairs this with a unique p19 chain 26 . IL-23 drives the differentiation of inflammatory T cells capable of secreting large amounts of tumor necrosis factor (TNF) and IL-17, which mediate tissue damage in autoimmune diseases 27, 28 . Furthermore, two Notch ligands, Delta-4 and Jagged-1, can be expressed by DCs and are capable of selectively inducing T H 1 or T H 2 differentiation, respectively 29 . The regulation of Notch ligands in human DCs has not been investigated.
Most studies so far have analyzed DC activation induced by single microbial compounds. However, pathogens express several TLR agonists that may engage different TLRs at different times and in distinct cellular compartments. A modest synergistic effect of TLR agonists on the production of inflammatory mediators, mainly TNF, by macrophage cell lines has been reported, but the effect on T cell priming has not been analyzed [30] [31] [32] . Here we sought to determine whether agonists triggering different TLRs may cooperate in DC activation. We found that in human DCs, agonists of TLR3 and TLR4 potently acted in synergy with an agonist of TLR8 in inducing IL-12, IL-23 and Delta-4 in amounts that were 50-to 100-fold higher than those induced by optimal concentrations of single agonists leading to enhanced and sustained T H 1-polarizing capacity. These results identify a 'combinatorial code' by which DCs discriminate pathogens and may provide a rationale for the design of adjuvants for T H 1 responses.
RESULTS
Selected TLR agonists act in synergy in IL-12p70 induction IL-12p70 is not efficiently elicited in human or mouse DCs by microbial stimuli alone and a second signal, provided by natural killer cells through IFN-g or by T helper cells through CD40L, is required for optimal induction 22, 23 . We sought to determine whether distinct TLRs may act in synergy in the induction of IL-12p70. As agonists, we used poly(I:C), LPS and the synthetic imidazoquinoline resiquimod (R848), which trigger TLR3, TLR4 and TLR8 (ref. 33), respectively. When added alone to human immature monocyte-derived DCs (MoDCs), the three agonists induced full DC maturation, as assessed by upregulation of HLA-DR, B7.1 (also called CD80) and B7.2 (also called CD86), as well as the production of small amounts of IL-12p70 ( Fig. 1a and Supplementary Fig. 1 online) . Notably, the simultaneous addition of R848 plus LPS or R848 plus poly(I:C) but not LPS plus poly(I:C) induced 20-to 50-fold more IL12p70 than did the addition of single agonists without further increasing HLA-DR and B7 expression. The same synergistic combinations of TLR agonists were also capable of inducing the production of large amounts of IL-12p70 in primary DCs isolated from human peripheral blood, which produced no or little IL-12p70 in response to single agonists (Fig. 1b) .
Mouse bone marrow-derived DCs do not express TLR8 but express the homologous receptors TLR7 and TLR9 (ref. 34) , which are triggered by R848 and CpG, respectively. When we challenged mouse DCs with TLR agonists alone or in combination, combinations of LPS or poly(I:C) plus CpG or R848 demonstrated considerable synergy, whereas other combinations were ineffective (Fig. 1c) .
We investigated the dose requirements for synergistic TLR stimulation by challenging human MoDCs with a range of concentrations of LPS, R848 and poly(I:C) (Fig. 1d,e) . Combinations of suboptimal doses of TLR agonists that were unable to induce IL-12p70 release when given alone induced IL-12p70 production in concentrations that were higher than those induced by optimal doses of single agonist, consistent with a synergistic mode of cytokine induction. In addition, combinations of nonstimulatory concentrations of TLR agonists were able to induce B7.2 expression, but the expression did not reach that induced by an optimal dose of the single agonists ( Supplementary  Fig. 1 online) . These results indicate that over a wide range of concentrations, selected TLRs potently act in synergy in the induction of IL-12 and, at limiting concentrations, they cooperate in the induction of costimulatory molecules.
Requirements for TLR synergy
The results reported above indicate that in both human and mouse DCs, the simultaneous activation of a TRIF-coupled receptor (TLR3 A R T I C L E S or TLR4) together with an endosomal receptor (TLR8 in humans and TLR7 or TLR9 in mice) leads to potent synergistic activation of IL12p70 production. We considered the possibility that the synergistic effect might be mediated by the production of IFN-b, which is rapidly and selectively induced by triggering TRIF-dependent TLRs 8 . However, the addition of exogenous IFN-b caused only a modest increase in IL-12 production and this increase occurred in all conditions tested, regardless of the nature of the stimulus or the concentration of IFN-b added ( Supplementary Fig. 2 online). Although we cannot exclude the possibility of a contribution of IFN-b or of IFN-b-induced genes in TLR synergy, we conclude that this pathway is unlikely to be the basis of TLR synergy. The fact that TLR3, TLR4 and TLR8 are present in different cellular compartments suggests that they may be triggered with different kinetics 15, 16 . In addition, after initial TLR stimulation, DCs become refractory to subsequent stimulation by the same or other TLR agonists 35, 36 . We therefore investigated whether the timing and the order of addition of TLR agonists would affect the extent of synergy in the induction of IL-12p70. For LPS and R848, synergy was maximal when the agonists were given within a 4-hour 'window' and regardless of the order of addition (Fig. 2a) . In contrast, for poly(I:C) and R848, synergy was maximal when poly(I:C) was added 4 h before R848 and was substantially decreased when poly(I:C) was added after R848 (Fig. 2b) . In all cases, there was no synergy when the two stimuli were given 24 h apart. Because of the different localization of the TLRs involved in synergistic activation, we considered the possibility that the synergy might be related to the redistribution of endosomal TLR8 at the cell surface induced by TLR3 or TLR4 engagement. The inhibitor of endosomal acidification bafilomycin A1 (refs. 16,37) abolished the effect of R848 both when it was used as single agonist and when it was given 5 h after LPS or poly(I:C) ( Supplementary Fig. 3 online and data not shown), indicating that TLR8 activation requires endosomal acidification also after TLR3 and TLR4 stimulation.
'Superinduction' of IL-12 by multiple agonists acting in synergy The results reported above indicate that synergistic TLR stimulation can directly trigger production of large amounts of IL-12p70 even in the absence of amplifying signals provided by IFN-g or CD40L 22, 23 . It was therefore important to establish whether the IL-12p70 production induced by synergistic TLR stimulation had already reached a maximal ceiling or could be further 'boosted' by IFN-g or CD40L. We stimulated human DCs with TLR agonists alone or in combination in the absence or in the presence of IFN-g or CD40L (Fig. 3) . As reported before 22, 23 , IFN-g and CD40L potently boosted IL-12p70 production induced by single TLR agonists. Notably, the amount of IL-12p70 elicited by a combination of single TLR agonists plus CD40L was similar to that elicited by TLR agonists acting in synergy in the absence of IFN-g or CD40L. In addition, IFN-g and CD40L were able to further increase the production of IL-12p70 induced by TLR combinations acting in synergy. Indeed, regardless of the type of TLR stimulation, IL-12p70 production was increased approximately 5-fold by IFN-g and approximately 50-fold by CD40L. In certain experiments, with maximal stimulatory conditions (synergistic TLR stimulation plus CD40L), 1 Â 10 6 DCs produced as much as 2 mg of IL-12p70. These findings indicate that DCs have a very high capacity to produce IL-12p70, which is 'deployed' only when they are triggered by multiple synergistic stimuli. Although IFN-g and CD40L can potently boost cytokine production, the final extent is set by the nature and combination of microbial stimuli. Stimulation of human DCs with synergistic combinations of TLR agonists (LPS plus R848 or poly(I:C) plus R848) led to a 4-to 6-fold increase in IL-12p40 mRNA and to a 40-to 60-fold increase in IL12p35 and IL-23p19 mRNA (Fig. 4a) . In addition, transcript abundance was more sustained after synergistic TLR stimulation. These findings indicate that the simultaneous triggering of two specific TLRs is particularly critical for inducing IL-12p35 and IL-23p19 mRNAs, which are limiting for IL-12 and IL-23 production.
We next investigated whether TLR synergy might also modulate the expression of the Notch ligands Delta-4 and Jagged-1, which promote T H 1 and T H 2 differentiation, respectively 29 . Delta-4 mRNA was undetectable in immature DCs and relatively few transcripts were induced by LPS, R848 or poly(I:C). Notably, synergistic combinations (LPS plus R848 or poly(I:C) plus R848) increased Delta-4 mRNA more than 100-fold (Fig. 4b) . In contrast, Jagged-1 mRNA was constitutively expressed in immature DCs and was transiently increased above basal expression by all stimuli. However, synergistic combinations of TLR agonists reduced by 90% the abundance of Jagged-1 mRNA at late time points (Fig. 4b) . Thus, synergistic stimulation of TLRs substantially increases the Delta-4/Jagged-1 expression ratio in DCs.
TLR synergy enhances the T H 1-polarizing capacity of DCs
The capacity of mature DCs to prime naive T cells is determined by the expression of MHC and costimulatory molecules, yet the T H 1-polarizing capacity is dependent on the actual secretion of IL-12 that is exhausted by 24 h after LPS stimulation 35 in the amount of IFN-g produced per cell). Furthermore, DCs stimulated for 48 h with LPS and R848 had persistent T H 1-polarizing capacity (Fig. 5) . We conclude that synergistic TLR stimulation both increases and sustains the T H 1-polarizing capacity of mature DCs.
TLR synergy affects cytokine production and release TLR-activated DCs produce a large variety of inflammatory cytokines and chemokines and upregulate the chemokine receptor CCR7, which drives them to the lymph node 38 . After synergistic TLR stimulation, mRNA of the inflammatory mediators cyclooxygenase-2 (COX-2), TNF and IL-6 was increased and this increase was sustained (Fig. 6a) . As a consequence, there was an increase in the amount of TNF and IL-6 released into the culture supernatant ( Supplementary Fig. 4 online) .
In the same stimulatory conditions, IFN-b mRNA expression was increased, whereas mRNA for the IFN-b-dependent chemokines was either unaffected (CXCL10) or showed only a modest increase (CCL5; Fig. 6a and data not shown). TLR agonists combinations had no synergistic effect on the expression of CCL3 and CCL22 mRNA, which peaked at early and intermediate time points, or on the expression of CCR7 mRNA, which was induced progressively and showed maximal expression at late time points (Fig. 6a and data not shown) . Finally, TLR agonists combinations boosted the expression and release into the supernatant of the immunomodulatory cytokine IL-10 ( Fig. 6a and Supplementary Fig. 4 online) .
Notably, although IL-1b mRNA was induced by single agonists and was increased only moderately by synergistic TLR stimulation (Fig. 6b) , there was no release of IL-1b protein into the supernatant after stimulation with highly purified LPS 39 or R848, but it was efficiently induced after synergistic stimulation (Fig. 6c) . This finding suggests that synergistic TLR stimulation provides signals necessary to trigger the 'inflammasome' 40 .
TLR synergy regulates a small set of genes To evaluate the effect of TLR synergy on global gene expression, we did microarray analysis of MoDCs stimulated for 2 and 8 h with LPS, R848 or LPS plus R848. Many genes (8,828 of the 14,550 expressed) were upregulated or downregulated by maturation stimuli in at least one of the conditions tested. For each of the 8,828 regulated transcripts, we determined the correlation between the 'fold change' induced by LPS plus R848 and the 'fold change' induced by the best of the single agonists (Fig. 7) . There were no substantial differences in gene expression pattern 2 h after stimulation (Fig. 7a) . In contrast, at the 8-hour time point, there was a notable change in gene expression. In synergistically stimulated DCs, most of the upregulated transcripts (including TNF, IL-6, IL-10, IL-12p40 and COX-2) were induced two-to fivefold more than in DCs stimulated by single agonists and, reciprocally, most of the downregulated genes were further suppressed. Notably, however, the expression of only approximately 1% of the genes induced by single TLR agonists was increased more than fivefold after synergistic TLR stimulation ( Fig. 7b and Table 1 ). Of these transcripts, most, including those encoding IL-12p35 (IL12A) and IL-23p19 (IL23A), were 'late genes' (expression peak at 8 h), whereas a few (IL29, EGR3, OSR2, DUSP2 and LOC400581) were 'early genes' (expression peak at 2 h) whose mRNA expression was sustained in synergistically stimulated DCs. This microarray analysis failed to demonstrate the genes encoding Jagged-1 and Delta-4 as being regulated by synergic stimulation. However, Jagged-1 downregulation (Fig. 4) was evident only at late time points (24 h), which are not present in the Affymetrix analysis, whereas the Delta-4-specific Affymetrix probes recognized a 3¢ untranslated region present in only one of the two splice variants recognized by the TaqMan probe used. We conclude that TLR synergy affects global gene expression only at late time points and that it selectively boosts a small number of genes of high relevance for the immune response.
TLR synergy sustains signaling
IkBz is a transcription factor that is transiently induced immediately after TLR triggering and is required for driving the expression of several genes that are induced at late time points 41 . As most of the genes affected by TLR synergy are regulated by IkBz 41 , we sought to determine whether this effect might correlate with increased IkBz expression. IkBz mRNA was induced within 1 h and was induced to a similar extent by all stimuli. However, when DCs were stimulated by synergistic TLR combinations, peak IkBz mRNA expression was broader, consistent with a higher availability of this essential transcription factor (Fig. 8a) .
As synergy was more evident at late time points, we investigated whether synergistic TLR stimulation might sustain signaling in maturing DCs (Fig. 8b) . The kinetics of p38 phosphorylation and IkBa degradation and resynthesis were similar in DCs activated by single TLR agonists or synergistic combinations. However, in the presence of a synergistic combination of R848 plus LPS or R848 plus poly(I:C), phosphorylation of the transcription factor c-Jun was enhanced and sustained up to 12 h, which is consistent with the late effect of TLR synergy in transcription.
DISCUSSION
Here we have shown that in DCs, TRIF-coupled TLRs (TLR3 and TLR4) potently acted in synergy with endosomal TLRs (TLR8 in humans and TLR7 and TLR9 in mice) in the induction of IL-12p70 and IL-23. Synergistic TLR stimulation preferentially affected the rate-limiting components IL-12p35 and IL-23p19, whose mRNA increased up to 50-fold over that induced by single agonists, while IL-12p40 mRNA was increased approximately 5-fold. The addition of CD40L (and, to a lesser extent, IFN-g) further boosted IL-12p70 production promoted by synergistic TLR stimulation up to as much as 2 mg per 1 Â 10 6 cells. These results indicate that DCs have very large capacity to produce IL-12 that is 'deployed' only in response to multiple stimuli acting in synergy. In addition, synergistic stimulation upregulated approximately 100-fold the T H 1-promoting ligand Delta-4 while downregulating to approximately 10% the T H 2 ligand Jagged-1. Consistent with these findings, DCs stimulated by TLR agonists acting in synergy showed increased and more sustained capacity to prime T H 1 responses. In contrast to the superinduction of T H 1-polarizing signals, upregulation of MHC and costimulatory molecules was not increased by TLR synergy over the expression induced by optimal concentrations of single agonists, indicating that the two 'programs' have different induction thresholds. This finding makes biological sense, as antigen presentation and costimulation are required for T cell activation and population expansion, whereas IL-12, IL-23 and Delta-4 promote the generation of potentially harmful effector cells and therefore need to be kept under strict control. Thus, the synergistic TLR stimulation may represent a 'combinatorial security code' (two microbial products in different cellular compartments) that ensures that powerful effectors will be generated only in response to invading pathogens.
Synergistic TLR stimulation is probably the rule in 'real life' , as pathogens may contain several TLR agonists that trigger TLRs in different cellular compartments. Our results have shown that the first contact with a TLR agonist opens a 'temporal window' for stimulation of another TLR that intensifies, complements and sustains the DC activation process. The integration of multiple stimuli over a defined 'temporal window' might allow a more effective response to invading pathogens than to soluble microbial products. For example, doublestranded RNA released by virus-infected cells may trigger TLR3 and prime DCs for a subsequent triggering of TLR8 by virus particles in the endosomal compartment. This mechanism may ensure that the polarizing signals will be delivered by those DCs that carry the pathogen in the endosomal compartment and therefore can present the relevant antigens.
Detailed kinetics analysis of several cytokine transcripts by real-time PCR combined with a global transcriptional analysis at 2 and 8 h after DC stimulation confirmed that only a limited number of genes were controlled by TLR synergy. Most of these genes are important in the immune response. These include the genes encoding IL-29 (IL29), granulocyte-macrophage colony-stimulating factor (CSF2), granulocyte colony-stimulating factor (CSF3) and leukemia inhibitory factor (LIF). In addition, dual TLR engagement, although modestly increasing IL-1b mRNA, potently triggered IL-1b release, a finding that extends the effect of synergy beyond transcription. The finding that synergy involved a TRIF-dependent TLR and an endosomal TLR would be consistent with the possibility that IFN-b, which is rapidly produced in response to triggering of TRIF-dependent TLRs 8 , can selectively enhance the response to triggering of endosomal TLRs. This mechanism is unlikely, as exogenous IFN-b had only a modest and variable effect on IL-12 production that was found regardless of the nature of the stimulus. Another possibility is that the synergy is mediated by redistribution of the endosomal TLRs induced by triggered TLR3 and TLR4. However, this possibility is also unlikely, as we found that the effect of R848 was dependent on endosomal acidification both when R848 was used as single agonist and when it was added after LPS or poly(I:C). The mechanism by which selected TLR pairs act in synergy in the induction of a few genes remains to be established. With the exception of the different TRIF usage and cellular localization, the signaling capabilities of TLRs acting in synergy are thought to overlap entirely. In particular, no distinct signaling pathways have been associated with endosomal TLRs. Nonetheless, it is possible that the potent synergy noted in the induction of a selected set of genes might depend on the induction of complementary signaling pathways still to be discovered.
A distinct possibility is that synergy results from sustained signaling provided by dual TLR engagement. This hypothesis is supported by two observations. The first is that synergistic TLR stimulation affected gene expression mainly at late time points. Indeed, the transcripts that were controlled by TLR synergy were either 'late genes' or 'early genes' whose expression is sustained in time. The second related observation is that in DCs stimulated by TLR agonists acting in synergy, c-Jun phosphorylation was sustained at late time points that coincided with the peak of mRNA expression of target genes, consistent with the pivotal function of the c-Jun kinase pathway and of the transcription factor AP-1 in controlling cytokine expression after TLR stimulation [42] [43] [44] . It remains to be established whether the sustained phosphorylation is due to increased activity of c-Jun kinase, blockade of phosphatase activity or more sustained signaling from engaged TLRs. The signals emanating from the TLRs acting in synergy might be integrated kinetically, resulting in more sustained signaling at late time points that is required for activation of the transcription of 'late genes' such as those encoding IL-12 and IL-23 or for sustaining the expression of 'early genes' .
Our findings might be relevant for the design of adjuvants capable of priming strong T H 1 and inflammatory responses. Although single agonists may provide suboptimal stimulation, synergistic pairs could fully 'deploy' the T H 1-polarizing capacity of DCs. This may be particularly relevant in newborns who have a low capacity for producing CD40L. Synergistic TLR stimulation could also be relevant for immunotherapy with ex vivo-treated DCs and for the induction of large amounts of systemic IL-12 for cancer therapy.
METHODS
Isolation and stimulation of DCs. Blood samples for transfusion were from the Basel Swiss Blood Center. Permission to do experiments on human primary cells was obtained from the Federal Office of Public Health (A000197/2 to F.S.). Circulating myeloid DCs were isolated with a combination of magnetic sorting and flow cytometry as described 18 . MoDCs were generated by culture of human monocytes isolated from buffy coats with CD14 microbeads (Miltenyi) and culture in medium supplemented with granulocyte-macrophage colonystimulating factor and IL-4 as described 45 . All DC preparations analyzed were more than 98% pure. Bone marrow-derived DCs were generated from BALB/c bone marrow cultured in granulocyte-macrophage colony-stimulating factor (R&D Systems) as described 46 . DCs were challenged with one or more of the following TLR agonists: 0.01 mg/ml (unless specified otherwise) of LPS (E. coli 055:B5 LPS (Sigma) or E. coli 0111:B4 LPS Ultra-Pure (InvivoGen)), 2.5 mg/ml of R848 (GLSynthesis), 20 mg/ml of poly(I:C) (Amersham) and 2.5 mg/ml of CpG oligodeoxynucleotide 1826 (5¢-CCATGACGTTCCTGACGTT-3¢).
Sorting and priming of naive T cells. Naive CD4 + CD45RA + T cells were isolated from cord blood with a combination of magnetic sorting and flow cytometry. MoDCs were stimulated for 12 or 48 h with TLR agonists, were washed and were plated with allogeneic naive T cells at a ratio of 1:10 in flatbottomed 96-well plates. After 5 d, proliferating cell populations were expanded with IL-2 and were analyzed on day 8.
Surface markers and cytokine production. Cell surface staining was done with directly conjugated monoclonal antibody (Immunotech). For detection of intracellular cytokines, T cells were stimulated for 5 h with phorbol 12-myristate 13-acetate plus ionomycin. Brefeldin A (10 mg/ml; Sigma) was added during the last 3 h. Cells were fixed with 2% paraformaldehyde, were permeabilized with PBS containing 2% FCS and 0.5% saponin and were stained with fluorescein isothiocyanate-labeled monoclonal antibodies specific for IFN-g and phycoerythrin-labeled monoclonal antibodies specific for IL-4 (PharMingen). Cells were analyzed on a FACSCalibur cytometer (Becton Dickinson). For intracellular staining of IL-12p40 and IL-12p70 in MoDCs, cells were stimulated first with LPS and then, after 5 h, with R848. Bafilomycin A1 (0.5 mM; Biomol) was added 2 h before R848 stimulation, brefeldin A was added 1 h after R848, and cells were incubated for another 10 h. Then, cells were fixed, permeabilized and stained with an allophycocyanin-labeled monoclonal antibody specific for IL-12p40 and/or IL-12p70 (PharMingen) and phycoerythrin-labeled monoclonal antibodies specific for anti-CD83 (Immunotech). Cytokines were measured in culture supernatants after 48 h of activation with the various stimuli using commercially available enzyme-linked immunosorbent assay kits for TNF, IL-6, IL-1b and IL-10 and for human and mouse IL-12p70 (R&D Systems).
Immunoblot analysis. Equal amounts of protein lysates were separated by SDS-PAGE and were transferred onto polyvinyldifluoride membranes. Filters were blocked with 5% dry, skim milk and were blotted with a specific primary antibody: rabbit antisera to polyclonal antibody to phosphorylated c-Jun (Ser-73) (New England Biolabs), monoclonal antibody to phosphorylated p38 (Sigma), polyclonal antibody to total p38 (Santa Cruz Biotechnologies) and monoclonal antibody to IkBa (Imgenex). Blots were then incubated with the appropriate horseradish peroxidase-conjugated secondary antiserum (Jackson Immunoresearch) and were visualized using the SuperSignal WestPico chemiluminescence system (Pierce).
Real-time quantitative RT-PCR. Total RNA was extracted with the Rneasy Mini Kit (Qiagen). Random hexamer and an MMLV reverse transcriptase kit (Stratagene) were used for cDNA synthesis. Transcripts were quantified by realtime quantitative PCR on an ABI PRISM 7700 Sequence Detector (PerkinElmer Applied Biosystems) with Applied Biosystems predesigned TaqMan Gene Expression Assays and reagents according to the manufacturer's instructions. For each sample, the mRNA abundance was normalized to the amount of 18S rRNA and is expressed as arbitrary units.
Microarrays and data analysis. MoDCs from three different donors were left untreated or were treated with LPS, R848 and the combination of LPS plus R848. RNA was extracted with the TRIzol method (Invitrogen Life Technologies) followed by an additional RNA 'cleanup' step with the RNAeasy purification kit according to the manufacturer's protocol (Qiagen). Total RNA (5 mg) was labeled and hybridized with the GeneChip Expression 3¢ Amplification One-Cycle Target Labeling kit on Affymetrix U133 2.0 Plus microarrays (Affymetrix). Washes and scanning were done according to Affymetrix protocols with Fluidics Station 400 and GeneChip Scanner 3000. Raw signals and 'present' or 'absent' calls were obtained with Affymetrix GCOS 1.2 software. Further data analysis was done with GeneSpring 7.2 (Silicon Genetics). Signal values below 0.01 were set to 0.01. The percentile of all the measurements in each sample was calculated using values for all genes not marked 'absent' . For each sample, gene measurements were first divided by the 50th percentile calculated using all genes not marked 'absent' on the microarray. Each gene value was then divided by the mean of its normalized measurements for the three untreated samples. Genes that did not present a signal intensity above 50 and that were not marked as 'present' in at least two of three replicates of at least one condition were 'discarded'; 14,550 genes passed this 'filter' . 'Fold changes' between treated and untreated cells at 2 h and 8 h were calculated for genes showing statistically significant differential expression in at least one of the conditions using a parametric test with variance assumed equal (analysis of variance) and a P value cutoff of 0.05, followed by the Benjamini and Hochberg false discovery rate multiple-test correction. Ratios between the 'fold changes' were then calculated for the selected 8,828 genes. For each gene, the best single agonist selected was the one able to induce the greater 'fold change' over control.
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